- Home
- ACAD vs NOG Comparison
ACAD vs NOG Comparison
Compare ACAD & NOG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACAD
- NOG
- Stock Information
- Founded
- ACAD 1993
- NOG 2006
- Country
- ACAD United States
- NOG United States
- Employees
- ACAD N/A
- NOG N/A
- Industry
- ACAD Biotechnology: Pharmaceutical Preparations
- NOG Oil & Gas Production
- Sector
- ACAD Health Care
- NOG Energy
- Exchange
- ACAD Nasdaq
- NOG Nasdaq
- Market Cap
- ACAD 3.5B
- NOG 2.8B
- IPO Year
- ACAD 2004
- NOG N/A
- Fundamental
- Price
- ACAD $23.53
- NOG $25.03
- Analyst Decision
- ACAD Buy
- NOG Buy
- Analyst Count
- ACAD 18
- NOG 8
- Target Price
- ACAD $27.94
- NOG $37.00
- AVG Volume (30 Days)
- ACAD 1.7M
- NOG 1.9M
- Earning Date
- ACAD 08-06-2025
- NOG 07-31-2025
- Dividend Yield
- ACAD N/A
- NOG 6.39%
- EPS Growth
- ACAD N/A
- NOG 6.78
- EPS
- ACAD 1.37
- NOG 6.08
- Revenue
- ACAD $996,283,000.00
- NOG $2,258,473,000.00
- Revenue This Year
- ACAD $13.28
- NOG $11.88
- Revenue Next Year
- ACAD $10.88
- NOG N/A
- P/E Ratio
- ACAD $17.19
- NOG $4.12
- Revenue Growth
- ACAD 22.42
- NOG 14.59
- 52 Week Low
- ACAD $13.40
- NOG $19.88
- 52 Week High
- ACAD $25.23
- NOG $44.31
- Technical
- Relative Strength Index (RSI)
- ACAD 61.47
- NOG 34.09
- Support Level
- ACAD $22.40
- NOG $26.50
- Resistance Level
- ACAD $24.06
- NOG $29.84
- Average True Range (ATR)
- ACAD 0.72
- NOG 1.24
- MACD
- ACAD 0.09
- NOG -0.19
- Stochastic Oscillator
- ACAD 76.96
- NOG 1.33
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.
About NOG Northern Oil and Gas Inc.
Northern Oil & Gas Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil and natural gas properties. Its principal business is crude oil and natural gas exploration, development, and production. The company's oil and natural gas sales come from three geographic areas in the United States: the Williston Basin (North Dakota and Montana), the Permian Basin (New Mexico and Texas), the Uinta Basin, and the Appalachian Basin (Pennsylvania and Ohio).